REYON Pharmaceutical Co., Ltd. (102460.KS)

KRW 13020.0

(-2.18%)

Market Cap (In KRW)

238.79 Billion

Revenue (In KRW)

151.07 Billion

Net Income (In KRW)

3.58 Billion

Avg. Volume

29.94 Thousand

Currency
KRW
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
11170.0-18650.0
PE
-
EPS
-
Beta Value
0.915
ISIN
KR7102460003
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Ms. Soon-Ock Jung
Employee Count
-
Website
https://reyonpharm.co.kr
Ipo Date
2010-06-10
Details
REYON Pharmaceutical Co., Ltd. manufactures and sells finished medicines and APIs in South Korea and internationally. The company offers its products under the areas of adrenal corticosteroides; angiotensin II receptor antagonists; anticholinergics; antiemetic; antihypertensives; anti-inflammatory enzymes; antilipidemic, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer; antispasmodics; benign prostatic hypertrophy; cough and cold remedies; cardiac stimulant; genitourinary smooth muscle relaxants; hemostatics; immunosuppressants; rheumatoid arthritis; local anesthetics; migraine drugs; miscellaneous cardiovascular system drugs; neuromuscular disorder related drugs; nootropics and neurotonics; NSAIDs; respiratory stimulants; skeletal muscle relaxants; and vasodilators. REYON Pharmaceutical Co., Ltd. was founded in 1955 and is headquartered in Seoul, South Korea.